Clene to Participate in the Maxim Group Virtual Healthcare Conference
Get Alerts CLNN Hot Sheet
Join SI Premium – FREE
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that Rob Etherington, Chief Executive Officer, will participate in a fireside chat with Naz Rahman, Senior Biotech Research Analyst, at the Maxim Group Virtual Healthcare Conference on June 22, 2023 at 1:00 PM ET.
This conference will be live on M-Vest. To attend, click here: Healthcare Virtual Conference | M-Vest.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
| Contacts: | |
| Media Contact | Investor Contact |
| Ignacio Guerrero-Ros, Ph.D., or David Schull | Kevin Gardner |
| Russo Partners, LLC | LifeSci Advisors |
| [email protected] | [email protected] |
| [email protected] | 617-283-2856 |
| (858) 717-2310 |
Source: Clene Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2nd Nature Named to TIME's List of the Best Inventions of 2026
- ELEPHAS PUBLISHES PEER-REVIEWED DATA IN CELL REPORTS MEDICINE DEMONSTRATING elive™ PLATFORM'S IMMUNOTHERAPY RESPONSE MEASUREMENT
- Akeneo Named a Leader in the 2026 Gartner® Magic Quadrant™ for Product Information Management Solutions
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share